Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells-Reference-Cited by-同舟云学术

Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells

Published:2014-03 Issue:3 Volume:22 Page:623-633
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Anurathapan Usanarat,Chan Robert C,Hindi Hakeem F,Mucharla Roopa,Bajgain Pradip,Hayes Brendan C,Fisher William E,Heslop Helen E,Rooney Cliona M,Brenner Malcolm K,Leen Ann M,Vera Juan F

Funder

Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Department of Defense Prostate Cancer Research Program

NIH

Adrienne Helis Malvin Medical Research Foundation

Dan L Duncan Cancer Center

Dan L. Duncan Chair

Fayez Sarofim Chair

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference38 articles.

1. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia;Porter;N Engl J Med,2011

2. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells;Kochenderfer;Blood,2012

3. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma;Pule;Nat Med,2008

4. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells;Till;Blood,2008

5. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans;Jensen;Biol Blood Marrow Transplant,2010

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies;Biomedicine & Pharmacotherapy;2024-09

2. Current Insights into CAR T-Cell-Based Therapies for Myelodysplastic Syndrome;Pharmaceutical Research;2024-08-26

3. CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma;Nature Communications;2024-08-21

4. Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment;eBioMedicine;2024-08

5. Universal CAR 2.0 to overcome current limitations in CAR therapy;Frontiers in Immunology;2024-06-19